Exploring the Impact of Intravenous Iron for Iron Deficiency in Heart Failure

This activity is jointly provided by Postgraduate Healthcare Education, LLC and Voxmedia, LLC.

This activity is supported by an independent educational grant from American Regent.


Gregory Lewis, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Stormi Gale, PharmD
Heart and Vascular Institute
Novant Health
Huntersville, North Carolina

Rajeev Malhotra, MD, MS
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Gregory Lewis, MD discloses the following:
Advisor for Amgen, American Regent, Edwards and NXT
Receives grant support from Applied Therapeutics, AstraZeneca, Cytokinetics, Pfizer and Rivus

Stormi Gale, PharmD has no actual or potential conflicts of interest in relation to this program.

Rajeev Malhotra, MD, MS discloses the following:
Advisor for Epizon Pharma, Myokardia/BMS, Renovacor, Third Pole
Receives grant support from American Heart Association, Amgen, Angea Biotherapeutics, National Heart, Lung, and Blood Institute-NIH, Wild Family Foundation
Receives royalties for patient on pharmacologic BMP inhibitors (along with Mass General Brigham), royalties from UpToDate for scientific content authorship, patent holder for gene therapies for vascular disease (through Mass General Brigham)

The clinical reviewer, Darrell Hulisz, RPh, PharmD has no actual or potential conflicts of interest in relation to this program.

John Kocsis, PhD, Jonathan Stotler, MAOM and Tammy Thompson of Voxmedia, LLC hereby state they do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Susanne Batesko-Kwas, MSHF, BSN, RN and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-24-030-H01-P
Credits: 1.5 hours (0.15 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 90 minutes


April 24, 2024


April 24, 2025


This activity is intended to meet the educational needs of managed care pharmacists.


To educate managed care pharmacists on the screening, diagnosis, and treatment for iron deficiency in heart failure patients to improve patient outcomes.


Upon completion of the educational activity, participants should be able to:

  • Recognize the deleterious consequences of iron deficiency, with or without anemia, in heart failure
  • Identify the drawbacks of and ineffective treatment with oral iron therapy for iron deficiency in heart failure patients
  • Interpret evidence with intravenous iron therapy for the treatment of iron deficiency in patients with heart failure
  • Explain the algorithm in the Heart Failure Society of America Scientific Statement for the management of iron deficiency in heart failure


Introduction (10 minutes)
Gregory Lewis, MD (Chair)

Pathophysiology, Clinical Manifestations, and Diagnosis of Iron Deficiency in HF (20 minutes)
Rajeev Malhotra, MD, MS

Clinical Evidence with Intravenous Iron in HF (20 minutes)
Gregory Lewis, MD

Case Presentation:  Best Practices for Managing Iron Deficiency in HF (20 minutes)
Stormi Gale, PharmD

Q&A (20 minutes)

How to Earn Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Voxmedia, LLC, or American Regent, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.